Observational studyBMC nephrology2026
Prognosis comparison in chronic kidney disease stages 4-5 patients with low parathyroid hormone level due to different causes.
Observational study in BMC nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundExisting studies have focused on secondary hyperparathyroidism with elevated PTH in CKD, but survival outcomes of CKD patients with low PTH remain underexplored. This study examines prognostic implications of PTH reduction from different etiologies.
methodsThis multicenter retrospective cohort study included CKD stages 4-5 patients with PTH < 150 pg/mL from the China Renal Data System, categorized into parathyroidectomy (PTX), Drug, and Unknown Causes (UC) groups based on low PTH etiology. Mortality was analyzed using Kaplan-Meier curves and Cox regression. Covariates were selected by univariate or LASSO regression. Inverse probability weighting was applied in sensitivity analyses to reduce confounding.
resultsA total of 17 175 patients were included: 423 in the PTX group, 10 519 in the Drug group, and 6 233 in the UC group. PTX group had the highest survival rate (79.44%) and lowest cardiovascular mortality (1.61%), followed by Drug group (69.21% and 4.60%) and UC group (50.76% and 9.83%) (all P < 0.01). Both Drug group and UC group were consistently associated with significantly higher mortality risk compared with the PTX group (both P < 0.05). After applying IPW to balance key covariates, PTX group remained associated with the lowest mortality risk (both P < 0.05). However, in some sensitivity analyses, no significant difference was observed between PTX group and Drug group.
conclusionsPharmacological therapy and PTX were associated with more favorable survival profiles than low PTH of unknown causes in patients with advanced CKD, though residual confounding due to baseline differences between groups cannot be fully excluded.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.